Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun’s ‘Game Changing’ Dengue Drug May Launch In Four Years

This article was originally published in PharmAsia News

Executive Summary

India's Sun Pharma has said it is developing a drug derived from traditional Indian medicine that could be a ‘game-changer’ in treating dengue, one of the most rapidly spreading mosquito-borne viral diseases in the world with no current treatment.

You may also be interested in...



Data Add To Strengthening Efficacy Case For Takeda Dengue Vaccine

Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.

Sun Dips Toe Into Vaccines With Dengvaxia Challenge

India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.

Share Fillip As Indian Pharma Crests US Regulatory Hump

For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel